ClinConnect ClinConnect Logo
Search / Trial NCT06814353

Intraoperatively Observed Site of Origin and Growth Pattern of Medulloblastoma

Launched by CHRISTIAN DORFER · Feb 2, 2025

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Medulloblastoma

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are referred for surgical resection of a medulloblastoma at a hospital with expertise in pediatric neurooncology
  • Both pediatric patients (aged \< 18 years at the time of diagnosis) and adult patients (aged \> 18 years at the time of diagnosis)
  • Exclusion Criteria:
  • Patients who are preoperatively admitted with severe tumor hemorrhage accompanied by clinical deterioration are excluded because these patients frequently do not receive magnetic resonance imaging as would be necessary for the present study, and the intraoperative assessment of the STO is limited in accuracy due to decreased visibility caused by the intra- and extratumoral hemorrhage.
  • If an intraoperative complication occurs (e.g. bleeding) which impairs visibility of the neuroanatomic structures and does not allow an accurate assessment of the STO, the patient is excluded.
  • If the histopathological and molecular analysis does not confirm the diagnosis of a MB, the patient has to be excluded as well.

About Christian Dorfer

Christian Dorfer is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, he leads initiatives that streamline the clinical trial process while ensuring adherence to regulatory standards and ethical guidelines. His extensive experience in the field enables him to effectively collaborate with research institutions, healthcare professionals, and stakeholders to foster advancements in treatment options. Through rigorous oversight and a patient-centered approach, Christian Dorfer is instrumental in driving the development of groundbreaking therapies that address unmet medical needs.

Locations

Berlin, , Germany

Vienna, , Austria

Tuebingen, , Germany

Utrecht, , Netherlands

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported